The protective effect of the newly discovered variant against coronary heart disease is likely to be caused by the below-average arterial stiffness of variant carriers.
An FDA-approved drug to lower blood sugar in adults with Type 2 diabetes also may decrease blood vessel dysfunction associated with aging, according to a new study from the University of Missouri School of Medicine.
Arterial stiffness may be a novel risk factor to be targeted in the prevention and treatment of insulin resistance and dyslipidemia from a young age, a new study published in Hypertension today suggests.